A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet.

Trial Profile

A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2011

At a glance

  • Drugs HLA DQ2 peptide vaccine (Primary)
  • Indications Coeliac disease; Food hypersensitivity
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2011 Results presented at the Digestive Disease Week in May 2011, according to an ImmusanT media release.
    • 16 Mar 2011 New trial record
    • 15 Mar 2011 Results will be presented at DDW-2011 according to an ImmusanT media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top